기자가 쓴 기사 더보기
(편집자 주 - 글로벌 제약기업인 애보트 (Abbott) 미국법인은 9월 23일 "자사의 씨밀락 (Similac) 제품에 위장장애와 소화불량 등을 불러 일으킬 수 있는 벌레나 유충이 들어가 있다"며 "리콜에 돌입한다"고 밝혔습니다.)
AUDIENCE: Consumer, Pediatrics
ISSUE: Possibility of the presence of a small common beetle in the product.
The FDA has determined that while the formula containing these beetles poses no immediate health risk, there is a possibility that infants who consume formula containing the beetles or their larvae, could experience symptoms of gastrointestinal discomfort and refusal to eat as a result of small insect parts irritating the GI tract.
BACKGROUND: The recall of these powder infant formulas includes certain Similac powder product lines offered in plastic containers, and certain Similac powder product lines offered in sizes such as 8-ounce, 12.4-ounce and 12.9-ounce cans. See the Product Photo page.
The recall includes powder infant formulas sold in the U.S., Puerto Rico, Guam and some countries in the Caribbean. No Abbott liquid infant formulas are impacted.
RECOMMENDATION: If symptoms are noted and persist for more than a few days, a physician should be consulted.
Products with affected lot numbers should be returned to Abbott at no cost to the consumer.
To immediately find out if the product in your possession is included in this recall, parents and caregivers should visit www.similac.com/recall , and type in their lot number to determine if their product is affected, or call (800) 986-8850.
| 인기기사 | 더보기 + |
| 1 | 베일 벗은 에이비엘바이오 비장의 카드㊤ siRNA와 그랩바디-B |
| 2 | 메지온 "희귀소아질환 '신속심사바우처'부활,미국 대통령 최종 승인" |
| 3 | 파킨슨병 권위자 한자리에…“이제는 임상에서 답해야 할 때” |
| 4 | 보로노이,비소세포폐암 환자 'VRN110755' 임상1상 IND 호주 승인 |
| 5 | "염증·혈관·섬유화·세포치료" 신장병 극복 K-바이오 4색 전략 |
| 6 | 베일 벗은 에이비엘바이오 비장의 카드㊦ siRNA가 ‘꿈의 기술’인 이유 |
| 7 | "파킨슨병 정복, 도파민 보충 넘어 질환 조절 패러다임 바뀐다" |
| 8 | 아미코젠, 인도 대리점 Aruni 통해 IEX 레진 첫 상업용 수주 확보 |
| 9 | 케어젠, 신규 전달 기술 '히알루로니다제 펩타이드' 최초 공개 |
| 10 | 정부 "첨단재생바이오, 추격자 넘어 선도자로" |
| 인터뷰 | 더보기 + |
| PEOPLE | 더보기 + |
| 컬쳐/클래시그널 | 더보기 + |
(편집자 주 - 글로벌 제약기업인 애보트 (Abbott) 미국법인은 9월 23일 "자사의 씨밀락 (Similac) 제품에 위장장애와 소화불량 등을 불러 일으킬 수 있는 벌레나 유충이 들어가 있다"며 "리콜에 돌입한다"고 밝혔습니다.)
AUDIENCE: Consumer, Pediatrics
ISSUE: Possibility of the presence of a small common beetle in the product.
The FDA has determined that while the formula containing these beetles poses no immediate health risk, there is a possibility that infants who consume formula containing the beetles or their larvae, could experience symptoms of gastrointestinal discomfort and refusal to eat as a result of small insect parts irritating the GI tract.
BACKGROUND: The recall of these powder infant formulas includes certain Similac powder product lines offered in plastic containers, and certain Similac powder product lines offered in sizes such as 8-ounce, 12.4-ounce and 12.9-ounce cans. See the Product Photo page.
The recall includes powder infant formulas sold in the U.S., Puerto Rico, Guam and some countries in the Caribbean. No Abbott liquid infant formulas are impacted.
RECOMMENDATION: If symptoms are noted and persist for more than a few days, a physician should be consulted.
Products with affected lot numbers should be returned to Abbott at no cost to the consumer.
To immediately find out if the product in your possession is included in this recall, parents and caregivers should visit www.similac.com/recall , and type in their lot number to determine if their product is affected, or call (800) 986-8850.